At the news
? MIXEDIMPACT 6/10 8-K filed Feb 26, 2026 at 07:18 ET
Anika Therapeutics reported flat Q4 revenue of $30.6M but full-year 2025 revenue declined 6% to $112.8M, driven by a 17% drop in OEM Channel sales. The company reaffirmed 2026 revenue guidance of $114-122.5M and announced CFO David Colleran's planned departure in May 2026. Despite improved gross margins and strong commercial channel growth, the negative revenue trend and executive departure outweigh positive operational improvements.
- Q4 2025 revenue: $30.6M (flat YoY), full-year 2025 revenue: $112.8M (down 6% YoY)
- Commercial Channel revenue grew 22% in Q4 and 15% for full year 2025
- OEM Channel revenue declined 12% in Q4 and 17% for full year 2025 due to U.S. pricing pressures
- CFO David Colleran will depart in May 2026 after transition period
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access